Targovax announces opening of Oslo University Hospital as site for ONCOS-102 trial in melanoma
Oslo, Norway, 24 September 2019 – Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today announces that Oslo University Hospital, has been included as a site in the ongoing ONCOS-102 trial in anti-PD1 refractory, advanced melanoma.
Recently, Targovax reported encouraging results from Part 1 of the phase I trial in anti-PD1 refractory melanoma combining ONCOS-102 with the checkpoint inhibitor Keytruda, showing 33% ORR and robust immune activation (see press release here). The trial has been running at three well reputed hospitals on the US East Coast.
Part 2 of the trial is currently enrolling patients, where an extended ONCOS-102 dosing regimen is being assessed. Targovax has now received all the necessary approvals and documentation required to open Oslo University Hospital, in Part 2 of the trial.
Magnus Jäderberg, CMO of Targovax, said: “As a Norwegian company, we are happy to open Oslo as a site for our ONCOS-102 melanoma trial. The trial has shown promising early data, and we are very pleased to be able to offer trial participation and this treatment option to Norwegian melanoma patients. We believe Oslo University Hospital will be a great addition to the trial consortium and facilitate faster recruitment in Part 2 of the trial”.
For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Media and IR enquires:
Andreas Tinglum – Corporate Communications (Norway)
Phone: +47 9300 1773